ViCapsys Life Sciences, Inc., (OTC:VICP) (“ViCapsys” or the “Company”) announced the appointment of Federico Pier as Chief Executive Officer of ViCapsys, effective February 15, 2022. Mr. Pier had been serving as interim President & CEO since August 2020.
We previously demonstrated that the incorporation of the chemokine CXCL12 into alginate microbeads supported long-term survival of microencapsulated auto-, allo-, and xenogeneic islets in murine models of diabetes without systemic immune suppression. The purpose of this study was to test whether CXCL12 could abrogate foreign body responses (FBRs)...
Alloantigen specific T cells have been shown to be required for allograft rejection. The chemokine, stromal cell derived factor-1 (SDF-1) at high concentration, has been shown to act as a T-cell chemorepellent and abrogate T-cell infiltration into a site of antigen challenge in vivo via a mechanism termed fugetaxis or chemorepulsion. We postulated that this mechanism could be exploited therapeutically and that allogeneic cells engineered to express a chemorepellent protein would not be rejected...
Islet transplantation represents a potentially curative approach for individuals with Type I Diabetes....
Pancreatic β‐cell replacement by islet transplantation for the treatment of type 1 diabetes (T1D) is currently limited by donor tissue scarcity and the requirement for lifelong immunosuppression...
Abstract: Type 1 diabetes (T1D) is a complex multifactorial disease characterized by autoimmune destruction of insulin producing pancreatic β cells...